Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours

por Tate, Sonya C, Burke, Teresa F, Hartman, Daisy, Kulanthaivel, Palaniappan, Beckmann, Richard P, Cronier, Damien M
Publicado 2016

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

por Torres-Guzmán, Raquel, Calsina, Bruna, Hermoso, Ana, Baquero, Carmen, Alvarez, Beatriz, Amat, Joaquín, McNulty, Ann M., Gong, Xueqian, Boehnke, Karsten, Du, Jian, de Dios, Alfonso, Beckmann, Richard P., Buchanan, Sean, Lallena, María José
Publicado 2017

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib

por Blosser, Wayne D., Dempsey, Jack A., McNulty, Ann M., Rao, Xi, Ebert, Philip J., Lowery, Caitlin D., Iversen, Philip W., Webster, Yue Wang, Donoho, Gregory P., Gong, Xueqian, Merzoug, Farhana F., Buchanan, Sean, Boehnke, Karsten, Yu, Chunping, You, Xin Tian, Beckmann, Richard P., Wu, Wenjuan, McNeely, Samuel C., Lin, Aimee Bence, Martinez, Ricardo
Publicado 2020